UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): November 8, 2010
Manhattan
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32639
|
36-3898269
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
48
Wall Street, Suite 1110
New
York, New York 10005
(Address
of principal executive offices) (Zip Code)
(212)
582-3950
(Registrant's
telephone number, including area code)
Not
applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
1
|
Item
8.01
|
Other
Events
|
On
November 8, 2010 Manhattan Pharmaceuticals, Inc. announced that it has been
awarded $244,279 in funding under the U.S. Government’s Qualifying Therapeutic
Discovery Project (QTDP) credit program. The Company has received
this funding for its lead product candidate AST-726 for the treatment of vitamin
B12 deficiency.
|
Item
9.01
|
Financial
Statements and Exhibits
|
|
(d)
|
|
Exhibits.
|
|
Exhibit
No.
|
Description |
|
99.1
|
Press
release dated November 8,
2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MANHATTAN
PHARMACEUTICALS, INC.
|
|||
|
Date: November 8,
2010
|
By:
|
/s/
Michael G. McGuinness
|
|
|
Michael
G. McGuinness
|
|||
|
Chief
Operating and Financial Officer
|
|||
2
Exhibit
99.1
Manhattan
Pharmaceuticals Awarded $245K Grant under the U.S. Qualified Therapeutic
Discovery Project Credit Program
NEW YORK, NY NOV 8, 2010 –
Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) announced today that it has been
awarded $244,279 in funding under the U.S. Government’s Qualifying Therapeutic
Discovery Project (QTDP) credit program. The Company has received
this funding for its lead product candidate AST-726 for the treatment of vitamin
B12 deficiency.
The QTDP
was created by Congress March 2010, as enacted under the Patient Protection and
Affordable Care Act and provides a tax credit or grant equal to 50% of eligible
costs and expenses for the tax years of 2009 and 2010. The QTDP was
designed to promote medical research and innovation that could improve health
and save lives. The program targeted projects in new innovative
therapies to prevent, diagnose, and treat acute and chronic
diseases. Companies that received QTDP grants were selected jointly
by the Treasury Department and the Department of Health and Human Services. The
grants are limited to companies with 250 or fewer employees. The Department of
Treasury further allocated the available funds among the most qualified
applicants, because the program was substantially oversubscribed.
About
Manhattan Pharmaceuticals, Inc.
Manhattan
Pharmaceuticals is a specialty healthcare product company focused on the
development and commercialization of innovative treatments for underserved
patient populations. The Company is currently focused on two lead
programs: AST-726, a nasally delivered vitamin B12
remediation treatment, and Hedrin®, a
novel, non-insecticide treatment for pediculosis (head lice), which is being
developed through a joint venture with Nordic Biotech. The company is
also studying AST-915 for the treatment of essential tremor and a topical GEL
product which may be commercialized as an OTC treatment for mild
psoriasis.
Note
Regarding Forward-Looking Statements
This press release contains
forward-looking statements regarding future
events. Such
statements are just
predictions and are subject to risks and uncertainties that could
cause the
company’s actual results to
differ materially. These risks are described in greater detail in the company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2009.
Contact
Manhattan
Pharmaceuticals, Inc.
Michael
G. McGuinness, Chief Operating
& Financial Officer
(212)
582-3950